文献速递肿瘤 PET/CT核素与放射性配体治疗

靶向神经降压素受体-1的64Cu、55Co和68Ga标记放射性药物的合成:利用多胺大环调整体内分布以实现诊疗一体化

Synthesis of 64Cu-, 55Co-, and 68Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles.
PubMed 文献 · J Nucl Med · 2024-08-01

本研究合成了一系列含多胺大环(MA)连接基和金属螯合剂的神经降压素拮抗剂,并用64Cu、55Co和68Ga标记,在H1299、HT29和Caco2肿瘤模型中行小动物PET/CT显像。结果表明,[64Cu]Cu-NT-CB-NOTA、[68Ga]Ga-NT-CB-NOTA和[55Co]Co-NT-CB-NOTA在NTSR-1阳性肿瘤中具有高摄取、高对比度和持续滞留。作者认为这些示踪剂可能成为靶向NTSR-1阳性癌症的优良诊断和治疗放射性药物。

要点

  • 含多胺大环的NT-CB-NOTA系列示踪剂在NTSR-1阳性肿瘤中显示高摄取和持续滞留。
  • [64Cu]Cu-NT-CB-NOTA在H1299模型中48小时肿瘤摄取为1小时的76.9%。
  • [55Co]Co-NT-CB-NOTA在HT29模型中24小时肿瘤摄取为1小时的60.2%。

核心结论

  • 连接不同含氮大环部分后,靶向NTSR-1放射性药物的肿瘤摄取和药代动力学性质得到很大改善。
  • 研究结果提示,用64Cu/67Cu、55Co/58mCo或68Ga标记的NT-CB-NOTA(177Lu在肿瘤中的作用有待未来研究确定)以及用64Cu/67Cu或55Co/58mCo标记的NT-Sarcage可能是靶向NTSR-1阳性癌症的优良诊断和治疗放射性药物。
  • 未来研究有必要将多胺大环单元引入其他配体以检验该方法的普适性。

研究设计与样本

  • 本研究合成了一系列含多胺大环连接基和金属螯合剂的神经降压素拮抗剂。
  • 使用H1299肿瘤模型在注射后1、4、24和48小时行小动物PET/CT显像,示踪剂包括[64Cu]Cu-DOTA-SR-3MA、[64Cu]Cu-NT-CB-NOTA、[68Ga]Ga-NT-CB-NOTA、[64Cu]Cu-NT-CB-DOTA和[64Cu]Cu-NT-Sarcage。
  • [55Co]Co-NT-CB-NOTA还在HT29(高NTSR-1表达)和Caco2(低NTSR-1表达)结直肠腺癌肿瘤模型中进行了测试。
  • 采用饱和结合实验和[55Co]Co-NT-CB-NOTA的内化实验检测示踪剂在HT29细胞中的特异性和内化。

主要发现

  • [64Cu]Cu-NT-CB-NOTA、[68Ga]Ga-NT-CB-NOTA和[55Co]Co-NT-CB-NOTA的体内PET显像显示,在NTSR-1阳性肿瘤中肿瘤摄取高、肿瘤-本底对比度高,且肿瘤滞留持续(注射后≤48小时)。
  • 在H1299肿瘤模型中,[64Cu]Cu-NT-CB-NOTA注射后48小时的肿瘤摄取为注射后1小时摄取的76.9%。
  • 在HT29肿瘤模型中,[55Co]Co-NT-CB-NOTA注射后24小时的肿瘤摄取为注射后1小时摄取的60.2%。
  • [64Cu]Cu-NT-Sarcage也显示高肿瘤摄取、低本底和注射后48小时高肿瘤滞留。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出,177Lu在肿瘤中的作用有待未来研究确定。
  • 作者指出,未来研究有必要将多胺大环单元引入其他配体以检验该方法的普适性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of theranostic radiotracers relies on their binding to specific molecular markers of a particular disease and the use of corresponding radiopharmaceutical pairs thereafter. This study reports the use of multiamine macrocyclic moieties (MAs), as linkers or chelators, in tracers targeting the neurotensin receptor-1 (NTSR-1). The goal is to achieve elevated tumor uptake, minimal background interference, and prolonged tumor retention in NTSR-1-positive tumors. Methods: We synthesized a series of neurotensin antagonists bearing MA linkers and metal chelators. The MA unit is hypothesized to establish a strong interaction with the cell membrane, and the addition of a second chelator may enhance water solubility, consequently reducing liver uptake. Small-animal PET/CT imaging of [64Cu]Cu-DOTA-SR-3MA, [64Cu]Cu-NT-CB-NOTA, [68Ga]Ga-NT-CB-NOTA, [64Cu]Cu-NT-CB-DOTA, and [64Cu]Cu-NT-Sarcage was acquired at 1, 4, 24, and 48 h after injection using H1299 tumor models. [55Co]Co-NT-CB-NOTA was also tested in HT29 (high NTSR-1 expression) and Caco2 (low NTSR-1 expression) colorectal adenocarcinoma tumor models. Saturation binding assay and internalization of [55Co]Co-NT-CB-NOTA were used to test tracer specificity and internalization in HT29 cells. Results: In vivo PET imaging with [64Cu]Cu-NT-CB-NOTA, [68Ga]Ga-NT-CB-NOTA, and [55Co]Co-NT-CB-NOTA revealed high tumor uptake, high tumor-to-background contrast, and sustained tumor retention (≤48 h after injection) in NTSR-1-positive tumors. Tumor uptake of [64Cu]Cu-NT-CB-NOTA remained at 76.9% at 48 h after injection compared with uptake 1 h after injection in H1299 tumor models, and [55Co]Co-NT-CB-NOTA was retained at 60.2% at 24 h compared with uptake 1 h after injection in HT29 tumor models. [64Cu]Cu-NT-Sarcage also showed high tumor uptake with low background and high tumor retention 48 h after injection Conclusion: Tumor uptake and pharmacokinetic properties of NTSR-1-targeting radiopharmaceuticals were greatly improved when attached with different nitrogen-containing macrocyclic moieties. The study results suggest that NT-CB-NOTA labeled with either 64Cu/67Cu, 55Co/58mCo, or 68Ga (effect of 177Lu in tumor to be determined in future studies) and NT-Sarcage labeled with 64Cu/67Cu or 55Co/58mCo may be excellent diagnostic and therapeutic radiopharmaceuticals targeting NTSR-1-positive cancers. Also, the introduction of MA units to other ligands is warranted in future studies to test the generality of this approach.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Fonseca Cabrera GO, Ma X, Lin W, et al. Synthesis of 64Cu-, 55Co-, and 68Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles. J Nucl Med. 2024. PMID: 38871388. doi:10.2967/jnumed.124.267469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。